What's new

Opinion/decision on a Paediatric investigation plan (PIP): Namuscla, Mexiletine hydrochloride, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Nervous system disorders, PIP number: P/0227/2024

Opinion/decision on a Paediatric investigation plan (PIP): Namuscla, Mexiletine hydrochloride, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Nervous system disorders, PIP number: P/0227/2024

Jun 24, 2025 - 13:50
 0
Opinion/decision on a Paediatric investigation plan (PIP): Namuscla, Mexiletine hydrochloride, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Nervous system disorders, PIP number: P/0227/2024
Opinion/decision on a Paediatric investigation plan (PIP): Namuscla, Mexiletine hydrochloride, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Nervous system disorders, PIP number: P/0227/2024
Read More

Tags:

Previous Article

Human medicines European public assessment report (EPAR): Tolucombi, telmisartan...

Next Article

Trump says Iran and Israel have violated ‘ceasefire’ brokered by the US

Related Posts

Human medicines European public assessment report (EPAR): Tecvayli, teclistamab, Date of authorisation: 23/08/2022, Revision: 6, Status: Authorised

Human medicines European public assessment report (EPAR...

Jun 4, 2025  0

Human medicines European public assessment report (EPAR): Xydalba, dalbavancin, Date of authorisation: 19/02/2015, Revision: 20, Status: Authorised

Human medicines European public assessment report (EPAR...

May 23, 2025  0

PSUSA/00000795/202410

PSUSA/00000795/202410

Jun 5, 2025  0